- Global Pharma News & Resources

Resolution of Cyber Security Incident

Leeds, 4 February 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company") the regenerative medical devices company, is pleased to confirm that due to actions taken following the cyber security incident, as originally  reported by the Company on 28 January 2020, the recovery has now been completed and all critical IT systems have been restored and brought back online. All processing in the Company's United States facility has also resumed with immediate effect.

The incident is projected to have a very short-term impact on the Company's ability to service customer demand, and it is anticipated that delayed orders will be dispatched over the coming weeks. Based on the Company's  initial investigations, there are no indications of any external transfer of sensitive or financial data, and the Company does not expect any associated costs of the system restoration to be material to the short-term cash flow.

The Company has implemented additional data security procedures to reduce the risk of future similar incidents from occurring, and will review its IT security procedures and service providers on an ongoing basis moving forward.   

The person responsible for this announcement is John Samuel, Executive Chairman.


Editor Details

  • Company:
    • Tissue Regenix Group
  • Name:
    • Tissue Regenix Group
Last Updated: 07-Feb-2020